HR 1003
HR 1003
as
emetics;
an
е,
ngers or
act
ates and
esia (TD)
t the
C CHE

1	WHEREAS, it is important that people taking medicines that work as
2	dopamine receptor blocking agents be monitored for tardive dyskinesia (TD) by
3	a healthcare provider as recommended by the American Psychiatric Association;
4	and
5	
6	WHEREAS, clinical research has led to the approval of certain
7	treatments for adults with tardive dyskinesia (TD) by the U.S. Food and Drug
8	Administration; and
9	
10	WHEREAS, recognition and treatment of tardive dyskinesia (TD) can make
11	a positive impact in the lives of many people experiencing this side effect
12	from taking medications that work as dopamine receptor blocking agents; and
13	
14	WHEREAS, the General Assembly can raise awareness of tardive
15	dyskinesia (TD) among the public and medical community,
16	
17	NOW THEREFORE,
18	BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE NINETY-FOURTH GENERAL
19	ASSEMBLY OF THE STATE OF ARKANSAS:
20	
21	THAT the House of Representatives:
22	(1) designate May 5-11, 2024 as "Tardive Dyskinesia Awareness Week";
23	and
24	(2) encourage anyone experiencing uncontrollable, abnormal, and
25	repetitive movements to consult their healthcare provider regarding their
26	symptoms.
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	